Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 · New England Journal of Medicine · 2,495 citations
https://doi.org/10.1056/nejmoa1113216
S
Sung‐Bae Kim
Ulsan College(KR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
717
Papers
42.0K
Citations
74
h-index
295
i10-index
Sung‐Bae Kim is an academic researcher from Ulsan College. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 74, co-authored 610 publications.
ORCID: 0000-0001-5588-8332Papers by this author
worksTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
2015 · New England Journal of Medicine · 2,084 citations
https://doi.org/10.1056/nejmoa1413513
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
2017 · New England Journal of Medicine · 1,840 citations
https://doi.org/10.1056/nejmoa1612645
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · The Lancet · 1,656 citations
https://doi.org/10.1016/s0140-6736(18)31999-8
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
2021 · The Lancet · 1,479 citations
https://doi.org/10.1016/s0140-6736(21)01234-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat